The National Institute for Health and Care Excellence has recommended Evrenzo (roxadustat) as an option for treating anemia associated with chronic kidney disease in adults with stage 3 to 5 CKD with no iron deficiency.
Evrenzo is the first hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be recommended by the National Institute for Health and Care Excellence (NICE), according to a press release from Astellas Pharma Ltd. The company said the recommendation means “roxadustat will be available as an alternative to erythropoietin stimulating agents (ESAs) for patients who